Form 4: Biogen Executive Michael McDonnell Reports Stock Transactions

EVP and CFO Michael McDonnell reports the acquisition and disposal of Biogen stock and restricted stock units on February 7, 2025.

Summary

• Michael McDonnell, EVP and Chief Financial Officer of Biogen Inc., filed a Form 4 detailing changes in beneficial ownership of company stock.
• On February 7, 2025, McDonnell acquired 2,335 shares of common stock and disposed of 786 shares at a price of $141.35.
• Also on February 7, 2025, McDonnell acquired 2,216 shares of common stock and disposed of 716 shares at a price of $141.35.
• These transactions involved the vesting of restricted stock units.
• Following these transactions, McDonnell directly owns 22,455 shares of Biogen common stock and 4,434 restricted stock units.

Sentiment

Score: 5

Explanation: This is a neutral report of stock transactions, with no inherent positive or negative sentiment. It simply reflects the executive's trading activity.

Industry Context

This filing is a routine disclosure of stock transactions by a company executive, which is common in publicly traded companies. It provides transparency into the executive's holdings and transactions in the company's stock.

Comparison to Industry Standards

• Executive stock transactions are a common occurrence in publicly traded companies like Biogen.
• Similar filings are made by executives at companies like Amgen (AMGN), Gilead Sciences (GILD), and Vertex Pharmaceuticals (VRTX) to disclose changes in their beneficial ownership of company stock.
• The reporting requirements are standardized by the SEC, ensuring transparency across the industry.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they provide insight into executive compensation and stock ownership.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Transactions, Restricted Stock Units, Biogen, BIIB, McDonnell, Executive Compensation